Table 1.
Ex Vivo Biodistribution Data for [89Zr]ZrDFO-Azepin-Trastuzumab in Mice Bearing SK-OV-3 Tumors
| Tissue | Normal Group (n = 5) |
Blocking Group (n = 6) |
||
|---|---|---|---|---|
| [89Zr]ZrDFO-Azepin-Trastuzumab (94 h)/%ID g−1 ± SDa | Tumor-to-Tissue Contrast Ratio ± SDb | [89Zr]ZrDFO-Azepin-Trastuzumab (94 h)/%ID g−1 ± SDa | Tumour-to-Tissue Contrast Ratio ± SDb | |
| Blood | 7.36 ± 0.96 | 8.94 ± 2.25 | 4.79 ± 1.18 | 2.53 ± 1.05 |
| Tumor | 65.79 ± 14.19 | 1.00 | 12.10 ± 4.06 | 1.00 |
| Heart | 2.58 ± 0.49 | 25.51 ± 7.32 | 2.22 ± 0.28 | 5.45 ± 1.95 |
| Lungs | 4.22 ± 0.75 | 15.57 ± 4.35 | 3.17 ± 0.60 | 3.82 ± 1.47 |
| Liver | 9.90 ± 1.44 | 6.64 ± 1.73 | 7.99 ± 2.56 | 1.51 ± 0.70 |
| Spleen | 5.28 ± 1.24 | 12.45 ± 3.97 | 5.64 ± 1.48 | 2.14 ± 0.91 |
| Stomach | 0.79 ± 0.15 | 83.03 ± 23.85 | 0.74 ± 0.19 | 16.36 ± 6.95 |
| Pancreas | 1.39 ± 0.28 | 47.27 ± 13.91 | 0.98 ± 0.10 | 12.39 ± 4.37 |
| Kidney | 4.16 ± 0.57 | 15.82 ± 4.03 | 3.35 ± 0.50 | 3.61 ± 1.33 |
| Small intestine | 1.28 ± 0.28 | 51.30 ± 15.70 | 1.33 ± 0.28 | 9.13 ± 3.62 |
| Large intestine | 0.74 ± 0.20 | 88.79 ± 30.95 | 0.79 ± 0.17 | 15.29 ± 6.10 |
| Fat | 2.22 ± 1.29 | 29.61 ± 18.31 | 0.78 ± 0.32 | 15.49 ± 8.24 |
| Muscle | 0.82 ± 0.30 | 79.84 ± 33.39 | 0.71 ± 0.12 | 17.05 ± 6.39 |
| Bone | 9.86 ± 2.29 | 6.67 ± 2.12 | 5.85 ± 4.24 | 2.07 ± 1.65 |
| Skin | 4.51 ± 0.73 | 14.58 ± 3.94 | 4.09 ± 0.86 | 2.96 ± 1.17 |
a
Uptake data are expressed as the mean %ID g−1 ± one standard deviation (SD).
b
Errors for the tumor-to-tissue ratios are calculated as the geometric mean of the standard deviations.